Articles related to GUIDELINES/RECOMMENDATIONS
Perspective: How Should the FDA Evaluate Psychedelic Medicine?
The FDA’s guidance on psychedelic medicine is a landmark in mental health treatment. With the potential to treat PTSD, addiction, and treatment-resistant depression, psychedelics could heighten the field. However, the guidance also highlights the need for rigorous study of these substances, particularly regarding their subjective effects and the role of psychological support.
Psychiatry November 14th 2023
Resolving the Paradox of Long-Term Benzodiazepine Treatment: Toward Evidence-Based Practice Guidelines
The commentary presents a compelling analysis of the paradoxical views on long-term benzodiazepine treatment, highlighting the need for evidence-based practice guidelines. It underscores the importance of considering both the challenges of withdrawal and the potential efficacy of long-term use in well-characterized DSM anxiety disorders.
Psychiatry November 7th 2023
Change to FDA Biosimilar Labeling Guidelines to Have Little Effect on Consumers
As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.
Clinical Pharmacology October 30th 2023
New Practice Guidelines for Determining Brain Death/Death by Neurologic Criteria Published
The introduction of these new guidelines marks a significant advancement in our understanding and determination of brain death. An emphasis on standardization and accuracy, these guidelines could change how we approach this critical aspect of medical practice.
Neurology October 24th 2023
Guidance Offered for Treating Patients Exposed to Xylazine
Stay informed about the increasing prevalence of xylazine in illegally manufactured fentanyl. Learn about its impact on patient care and discover strategies for effective treatment and harm reduction.
Emergency Medicine October 18th 2023
USPSTF Releases Recommendation for Screening for Lipid Disorders in Children, Adolescents
Stay updated on the USPSTF’s stance on lipid disorder screening in asymptomatic youth—a topic that directly impacts our strategies for early detection and intervention.
Endocrinology, Diabetes, Metabolism October 11th 2023